Delpacibart Braxlosiran FSHD Shows Promise in D...

By João L. Carapinha

June 11, 2026

Novartis has achieved a key clinical milestone with delpacibart braxlosiran FSHD, as its FORTITUDE biomarker cohort successfully met the primary endpoint by substantially suppressing DUX4-driven gene expression and reducing muscle damage markers i...